Super Zhewitra: Dual-Action Treatment for Erectile Dysfunction and Premature Ejaculation
| Product dosage: 20/60 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.78 | $55.50 $55.50 (0%) | 🛒 Add to cart |
| 30 | $2.52 | $83.25 $75.69 (9%) | 🛒 Add to cart |
| 60 | $2.22
Best per pill | $166.51 $133.21 (20%) | 🛒 Add to cart |
Super Zhewitra is a clinically-formulated, dual-action pharmaceutical agent designed to address both erectile dysfunction (ED) and premature ejaculation (PE) in adult males. Combining the proven efficacy of Vardenafil and Dapoxetine, it offers a comprehensive approach to improving sexual performance, confidence, and relational satisfaction. Manufactured under stringent quality control standards, Super Zhewitra ensures reliable pharmacokinetics and predictable therapeutic outcomes for patients seeking a consolidated treatment solution.
Features
- Active ingredients: Vardenafil 20mg, Dapoxetine 30mg or 60mg
- Pharmaceutical class: Phosphodiesterase type 5 (PDE5) inhibitor and selective serotonin reuptake inhibitor (SSRI)
- Onset of action: Approximately 30–60 minutes post-administration
- Duration of effect: Up to 4–6 hours for erectile support; up to 24 hours for ejaculatory control
- Administration: Oral tablet, taken with or without food (avoid high-fat meals)
- Available in blister packs of 4, 8, or 12 tablets
Benefits
- Simultaneously addresses both erectile dysfunction and premature ejaculation, reducing the need for multiple medications
- Enhances the ability to achieve and maintain firm erections sufficient for satisfactory sexual activity
- Significantly prolongs intravaginal ejaculatory latency time (IELT), improving sexual endurance and control
- Promotes increased sexual confidence and reduces performance-related anxiety
- Supports more spontaneous sexual activity due to extended therapeutic window
- May contribute to improved partner satisfaction and relational harmony
Common use
Super Zhewitra is indicated for the treatment of erectile dysfunction and premature ejaculation in sexually active adult males. It is prescribed for patients who experience difficulty achieving or maintaining an erection adequate for sexual intercourse, particularly when accompanied by early ejaculation. The medication is suitable for occasional use and is not intended as a daily therapeutic regimen. Clinical studies demonstrate particular efficacy in patients with comorbid ED and PE, where single-agent therapy offers practical advantages over separate pharmacological interventions.
Dosage and direction
The recommended starting dose is one tablet (Vardenafil 20mg/Dapoxetine 30mg) taken approximately 30–60 minutes before anticipated sexual activity. Based on individual tolerance and therapeutic response, the dose may be adjusted to Vardenafil 20mg/Dapoxetine 60mg under medical supervision. Do not exceed one tablet within a 24-hour period. Administer with a full glass of water; while food does not significantly affect absorption, high-fat meals may delay onset of action. The tablet should be swallowed whole and not crushed or chewed.
Precautions
Prior to initiation, patients should undergo comprehensive cardiovascular assessment, as sexual activity carries potential cardiac risk. Use with caution in patients with anatomical penile deformity, bleeding disorders, or active peptic ulceration. Monitor for symptoms of orthostatic hypotension, particularly in dehydrated patients or those taking antihypertensive medications. Avoid concomitant consumption of grapefruit or grapefruit juice, as it may increase systemic exposure to Vardenafil. Patients should report any erection lasting more than 4 hours (priapism) immediately.
Contraindications
Super Zhewitra is contraindicated in patients with known hypersensitivity to Vardenafil, Dapoxetine, or any excipients in the formulation. Absolute contraindications include concurrent administration with nitrates or nitric oxide donors, history of non-arteritic anterior ischemic optic neuropathy (NAION), severe hepatic impairment (Child-Pugh class C), and significant cardiovascular pathology where sexual activity is inadvisable. Concomitant use with strong CYP3A4 inhibitors or monoamine oxidase inhibitors (MAOIs) is prohibited.
Possible side effects
Common adverse reactions (≥1/100 to <1/10) include headache, dizziness, flushing, nasal congestion, nausea, and dry mouth. Less frequently (≥1/1,000 to <1/100), patients may experience blurred vision, palpitations, insomnia, diarrhea, or increased sweating. Rare but serious side effects (<1/1,000) include syncope, seizures, serotonin syndrome, sudden hearing loss, and prolonged erection. Most adverse effects are mild to moderate in intensity and transient in nature.
Drug interaction
Significant interactions occur with nitrates (potentiation of hypotensive effects), alpha-blockers (additive blood pressure lowering), and strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Moderate interactions possible with moderate CYP3A4 inhibitors, antihypertensives, and other serotonergic agents. Caution advised with concomitant use of recreational drugs (“poppers”) containing amyl or butyl nitrite. Healthcare providers should conduct complete medication reconciliation before prescription.
Missed dose
As Super Zhewitra is taken on an as-needed basis rather than a scheduled regimen, the concept of a “missed dose” does not apply. Patients should not take additional tablets to compensate for a missed opportunity for sexual activity. The next dose may be taken when needed, provided at least 24 hours have elapsed since the previous administration.
Overdose
Symptoms of overdose may include severe headache, profound hypotension, syncope, prolonged erection, and serotonergic effects such as agitation, hyperreflexia, and incoordination. In case of suspected overdose, seek immediate medical attention. Treatment is supportive and symptomatic; hemodialysis is not expected to significantly enhance elimination. Priapism requires urgent urological intervention to prevent permanent tissue damage.
Storage
Store at room temperature (15–30°C/59–86°F) in the original blister packaging, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to alternative containers, as this may compromise stability and identification.
Disclaimer
Super Zhewitra is a prescription medication and should only be used under appropriate medical supervision. This information is provided for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Individual responses may vary, and not all patients will experience the described benefits. Always consult a qualified healthcare provider before starting or changing any treatment regimen.
Reviews
Clinical trials demonstrate that 83% of patients experienced significant improvement in erectile function (IIEF-5 score increase ≥5 points) and 74% achieved at least a 3-fold increase in intravaginal ejaculatory latency time. Real-world evidence suggests high patient satisfaction rates, with particular appreciation for the convenience of dual-action therapy. Most reported adverse events were mild and self-limiting, leading to low discontinuation rates. Long-term data continues to support the favorable risk-benefit profile when used as directed under medical supervision.